Autoimmune disorders, rheumatoid arthritis, systemic inflammation, and immune dysregulation
330 articles
Virtual patient replicas built from multimodal data may slash trial costs, generate synthetic control arms, and predict treatment response in IBD.
Senescent T cells fuel psoriasis, eczema, and rosacea through toxic secretions. New therapies may finally break the cycle.
A new in vitro study shows Thymosin α1 triggers dendritic cells to release IL-15, boosting CD8+ T cell killing and reducing HIV reservoir size.
A clinical case from Japan illustrates how cryoglobulinemia can drive membranoproliferative glomerulonephritis, a serious kidney complication.
A 2025 meta-analysis of 11 RCTs finds Tα1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
A major review maps emerging immunotherapies—from JAK inhibitors to microbiome interventions—that could transform care for celiac and food allergy patients.
A new veterinary sedative is contaminating the illegal fentanyl supply, posing novel overdose risks that standard treatments may not reverse.
A 2026 NEJM commentary examines the alarming resurgence of measles in 2025 and what it means for public health and clinical practice.
New research reveals that mitochondrial energy pathways directly govern dendritic cell immune activation, with major implications for cancer and autoimmune therapies.
A Stanford RCT finds pulsed electromagnetic field therapy significantly reduces thumb CMC osteoarthritis pain at 6 weeks, even after treatment ends.
Mice lacking the PERP apoptosis gene develop faulty thymic immune screening, accumulating self-reactive T-cells that trigger arthritis as they age.
Pyruvate, a core metabolic molecule, suppresses interferon signaling by directly modifying STAT1 — linking metabolism to immune control.
